Top 5 Mid-Cap Stocks at Discount

Tanushree Jaiswal Tanushree Jaiswal

Last Updated: 31st July 2023 - 09:53 am

Listen icon

Mid-cap companies as the name indicate, fall right in the middle, between large and small-cap companies. Mid-cap stocks are the respective shares of the companies that comprise a market capitalization in between ₹ 5,000 Crore to  ₹20,000 Crore. As per SEBI, the listed companies which are ranked from 101 to 250 company in the Indian stock exchanges (NSE & BSE) in the terms of market capitalization are said to be Mid-Cap Stocks. Bharat Electronics, Exide Industries, Bharat Forge, etc. are some of the Mid-cap stocks. Nifty has a benchmark Mid-cap Index in India known as Nifty Midcap 50 which holds the top 50 most traded mid-cap stocks in the market.

The mid-cap stocks at discount are:

1. Piramal Enterprises

The Piramal Enterprise share price has decreased by 53% from its 52-week high of Rs 2084, with the previous close on 20 July' 2023 at Rs 976. The average estimated share price target is Rs 1095, a potential upside of around 12%.

Key Highlights:

I. Strategic Loan Mix: PEL aims to shift loan mix towards retail lending (67% of AUM by FY26) to mitigate cyclicality in the wholesale business.
II. De-risking Wholesale Book: PEL enhanced granularity and provisioned 55% for Stage-3 assets in the wholesale book, with positive developments expected from FY23-24 onwards.
III. Potential Stake Unlocking: PEL holds an 8.34% stake in Shriram Finance, which may be unlocked in the next 12-18 months, providing additional value to shareholders 
IV. Expansion in Retail Business: PEL is expanding unsecured lending by partnering with Fintech and Consumer Tech companies, offering an attractive yield of 18% on advances and a robust ROA of around 5%.

Key Risks: 

Potential risks include slower retail lending growth, delayed resolution in Wholesale 1.0, and unforeseen issues in Wholesale 2.0 despite risk management measures.

Financial Performance:

Robust Balance Sheet: PEL maintains a strong balance sheet with a net worth of ₹ 31,000cr and cash & liquid investments of ₹ 7,430cr as of March 2023.

Outlook:

he company is showing great growth trajectory to cross the current valuation of the stock.

Financial Summary:

Y/E Mar (Cr)

FY23

NII

4,893

NIM (%)

5.85

PPOP

2,830

PAT

1,514

BV (Rs.)

1,301

PBV

0.59

ROE

5.61

ROA

1.65

 

2. Gland Pharma

The Gland Pharma share price has decreased by 53% from its 52-week high of ₹ 2606, with the previous close on 20 July' 2023 at ₹ 1237. The average estimated share price target is ₹ 1429, a potential upside of around 16%.

Key Highlights:

I. US Market: GLAND's revenue decline in the US market was attributed to inventory rationalization, high price pressure, and a higher base from COVID-19 related products sales.
II. India Business: Impact on business due to production line shutdown and reduced business from domestic B2C division.
III. RoW Business: Softer off-take in the ROW market and penem production line shutdown as part of capacity expansion.

Key Risks:

I. USFDA inspection outcomes may impact revenue growth.
II. Entry of new players could increase pricing pressure in the injectable portfolio.
III. Delay in launching Biosimilar in the market.

Financial Performance:

I. Revenue declined by 28.8% YoY, with weak performance in the US, India, and RoW markets.
II. Gross margins improved by 300bps, EBITDA margins at 21.5% down 100bps.
III. Reported PAT fell by 72% YoY due to lower sales and low operating profitability.

Outlook:

Expecting similar growth for GLAND in core markets and high single-digit growth in India and RoW over the long term

Financial Summary:

Y/E Mar (Cr)

FY23

Net Sales

3,617

EBITDA

1,019

Net Profit

776

EPS (Rs)

47

P/BV (x)

16.6

EV/EBITDA (x)

2.7

ROE (%)

11

 

3. Rajesh Exports

The Rajesh Exports share price has decreased by 50% from its 52-week high of ₹ 1028, with the previous close on 20 July' 2023 at ₹ 517. The average estimated share price target is ₹ 1100, a potential upside of around 113%.

Key Highlights:

Rajesh Exports Signed Pact for Lithium-ion Cell Factory:
I. Bengaluru-based Rajesh Exports signs pact with Ministry of Heavy Industries and Karnataka government.
II. The agreement is for setting up a 5 GWh lithium-ion cell factory in Karnataka.
III. The project is part of the ₹  181 billion production-linked incentive (PLI) program for advanced chemistry lithium-ion cells.

Government Support and Incentives:

I. Ministry of Heavy Industries and Karnataka government assure all required support for the Giga Factory.
II. Tailor-made incentive package provided by the state government for the project.

Key Risk:

Dividend pay-out has been low at 2.83% of profits over last 3 year. 

Financial Performance:

I. Company is almost debt free.
II. Company is expected to give good quarter.

Outlook:

The company is the single largest constituent of the gold business. Rajesh Exports aims to foray into advanced technology solutions for clean and green energy storage.

Financial Summary:

Y/E Mar (Cr)

FY23

Net Sales

3,39,690

EBITDA

1,555

Net Profit

1,478

EPS (Rs)

49

P/BV (x)

1.03

EV/EBITDA (x)

8.8

ROE (%)

10.05

 

4. Aarti Industries

The Aarti Industries share price has decreased by 50% from its 52-week high of ₹ 924, with the previous close on 20 July' 2023 at ₹ 466. The average estimated share price target is ₹ 562, a potential upside of around 21%.

Key Highlights:

I. Established in 1984, Aarti Industries is a global specialty chemical company.
II. Operates in key value chains with a major presence in the US, Europe, and Japan.
III. Holds a top-five global ranking for 75% of its portfolio.
IV. 200+ products sold to 700+ domestic and 400+ export customers in 60 countries.

Key Risk and Financial Performance:

I. Challenging FY23 due to global supply chain disruptions and inflationary pressures.
II. Chemical business EBITDA grew over 2x in the last five yea₹ 
III. Commercialized new facilities and ongoing expansions on track.
IV. Volume growth expected to be robust in FY24 (~25%).
V. EBITDA growth guidance remains unchanged at 25%.
VI. Capex projects to be commissioned in FY24-25 for further capacity expansion.

Outlook:

I. Upcoming capex of₹ 2500-3000 crore to boost specialty chemical revenue growth.
II. Increasing share of value-added business portfolio.
III. Expanding product range with new chemistries and value-added products.

Financial Summary:

Y/E Mar (Cr)

FY23

Net Revenue

6,619

EBITDA

1,089

EBITDA Margin

17%

PAT

546

EPS (Rs)

15

EV/EBITDA (x)

30

PE (x)

54

ROE (%)

11

ROCE (%)

10

 

5. Adani Power

The Adani Power share price has decreased by 44% from its 52-week high of ₹ 433, with the previous close on 20 July' 2023 at ₹ 244. 

Key Highlights:

I. The project in Mannar and Pooneryn in Sri Lanka's Northern Province will be completed by January 2025.
II. The projects include a 500 MW wind project, development of Colombo Port West Container Terminal, and producing green Hydrogen.
III. The total investment in the projects is nearly $1 billion, showcasing Adani Group's growing footprint in the regional port and energy sector.  The Group previously entered the Colombo Port project as the majority stakeholder after a different development plan was cancelled.

Renewable Energy Cooperation and Development in Sri Lanka:

Sri Lanka and India signed agreements on renewable energy cooperation and development of Trincomalee as an energy hub. A permit for a joint venture between Ceylon Electricity Board & NTPC for a solar park in Sampur, Trincomalee district, was issued.

Key Risk:

I. Company is not paying out dividend
II. Promoters have pledged 25.1% of their holding.

Financial Performance:

I. Company has delivered good profit growth of 48.1% CAGR over last 5 year 
II. Company's working capital requirements have reduced from 103 days to 74.2 days.

Outlook:

I. This company is likely to have a strong quarter. 
II. Over the past 5 year, it has shown impressive profit growth at an average rate of 48.1% annually and expected to maintain.

Financial Summary:

Y/E Mar (Cr)

FY23

Net Revenue

38,773

EBITDA

10,096

EBITDA Margin

26%

PAT

7,675

EPS (Rs)

28

EV/EBITDA (x)

9.3

PE (x)

8.5

ROE (%)

44

ROCE (%)

15.8

 

Top 5 Mid-Cap Stocks at Discount:

Stock Name

CMP

Target

Potential Upside

Piramal Enterprises

Rs. 1091.55

Rs. 1095

12%

Gland Pharma

Rs. 1197.8

Rs. 1429

16%

Rajesh Exports

Rs. 513.45

Rs. 1100

113%

Aarti Industries

Rs. 464.5

Rs. 562

21%

Adani Power

Rs. 256.00

Rs. 300

22%

*Summary(as on 26th July 2023)

How do you rate this article?
Characters remaining (1500)

FREE Trading & Demat Account
+91
''
Resend OTP
''
''
Please Enter OTP
''
By proceeding, you agree T&C*
Mobile No. belongs to

Indian Stock Market Related Articles

List Of Maharatna Companies In India

by Tanushree Jaiswal 9th Aug 2024

Why Quant Mutual Funds Are Outperforming?

by Tanushree Jaiswal 5th Jul 2024

NSE's 90% Cap on SME IPO Listing Prices

by Tanushree Jaiswal 5th Jul 2024

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Want to Use 5paisa
Trading App?